These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19204418)

  • 41. Managing asthma in the 21st century: role of pharmacogenetics.
    Wechsler ME
    Pediatr Ann; 2006 Sep; 35(9):660-2, 664-9. PubMed ID: 16999299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moving Pharmacogenetics Into Practice: It's All About the Evidence!
    Luzum JA; Petry N; Taylor AK; Van Driest SL; Dunnenberger HM; Cavallari LH
    Clin Pharmacol Ther; 2021 Sep; 110(3):649-661. PubMed ID: 34101169
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Defining the opportunity for pharmacogenetic intervention in primary care.
    Grice GR; Seaton TL; Woodland AM; McLeod HL
    Pharmacogenomics; 2006 Jan; 7(1):61-5. PubMed ID: 16354125
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS.
    Fargher EA; Eddy C; Newman W; Qasim F; Tricker K; Elliott RA; Payne K
    Pharmacogenomics; 2007 Nov; 8(11):1511-9. PubMed ID: 18034616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
    Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
    J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?
    Ozdemir V; Shear NH; Kalow W
    Drug Saf; 2001; 24(2):75-85. PubMed ID: 11235820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effect of Temporal Information on Placebo Analgesia and Nocebo Hyperalgesia.
    Camerone EM; Piedimonte A; Testa M; Wiech K; Vase L; Zamfira DA; Benedetti F; Carlino E
    Psychosom Med; 2021 Jan; 83(1):43-50. PubMed ID: 33109926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The nocebo effect of drugs.
    Planès S; Villier C; Mallaret M
    Pharmacol Res Perspect; 2016 Apr; 4(2):e00208. PubMed ID: 27069627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [State of the art of pharmacogenetic diagnostics in drug therapy].
    Kirchheiner J; Seeringer A; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nocebo Responses in Brain Diseases: A Systematic Review of the Current Literature.
    Zis P; Mitsikostas DD
    Int Rev Neurobiol; 2018; 139():443-462. PubMed ID: 30146057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Considerations for safety pharmacogenetics in clinical practice.
    Frueh FW
    Drug Discov Today; 2011 Oct; 16(19-20):898-901. PubMed ID: 21888988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research.
    Daud ANA; Bergsma EL; Bergman JEH; De Walle HEK; Kerstjens-Frederikse WS; Bijker BJ; Hak E; Wilffert B
    BMC Pregnancy Childbirth; 2017 Apr; 17(1):120. PubMed ID: 28410576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Harnessing the placebo effect: Exploring the influence of physician characteristics on placebo response.
    Howe LC; Goyer JP; Crum AJ
    Health Psychol; 2017 Nov; 36(11):1074-1082. PubMed ID: 28277699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Personalised pharmacogenetics. Evidence-based guidelines and clinical application of pharmacogenetic diagnostics].
    Stingl JC; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1509-21. PubMed ID: 24170080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics in drug discovery and development: a translational perspective.
    Roses AD
    Nat Rev Drug Discov; 2008 Oct; 7(10):807-17. PubMed ID: 18806753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delivering pharmacogenetic testing in a primary care setting.
    Mills R; Voora D; Peyser B; Haga SB
    Pharmgenomics Pers Med; 2013; 6():105-12. PubMed ID: 24101877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. It is not just the drugs that matter: the nocebo effect.
    Wojtukiewicz MZ; Politynska B; Skalij P; Tokajuk P; Wojtukiewicz AM; Honn KV
    Cancer Metastasis Rev; 2019 Jun; 38(1-2):315-326. PubMed ID: 31203560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Nocebo--the antipode to placebo].
    Kaada B
    Nord Med; 1989; 104(6-7):192-8. PubMed ID: 2734096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.